Basilea Pharmaceutica AG (OTC:BPMUF) Q4 2024 Earnings Conference Call February 18, 2025 10:00 AM ET
Company Participants
David Veitch – Chief Executive Officer
Adesh Kaul – Chief Financial Officer
Marc Engelhardt – Chief Medical Officer
Conference Call Participants
Brian White – Calvine
Jyoti Prakash – Edison Group
Raghuram Selvaraju – H.C. Wainwright
Lee Chien-Hsun – Pareto Securities
Thomas Meyer – Baader Helvea
Operator
Ladies and gentlemen, welcome to the Basilea Pharmaceutica Full-Year Results 2024 Conference Call and Live Webcast. I’m Sandra, the chorus call operator. I would like to remind you that all participants will be in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. [Operator Instructions] The conference must not be recorded for publication or broadcast.
At this time, it’s my pleasure to hand over to David Veitch, Chief Executive Officer. Please go ahead, sir.
David Veitch
Thank you, Sandra. Hello, I’m David Veitch, CEO of Basilea, and I would like to welcome you to our conference call and webcast, reviewing our financial results and key achievements for the full-year 2024 as well as highlighting our key future value drivers. For further detailed information, please see the Ad hoc announcement issued this morning and also our Annual Report. Both these documents are available on our website at basilea.com.
I’d like to mention that this call contains forward-looking statements. Joining me on our call today are Adesh Kaul, our Chief financial officer; and Dr. Marc Engelhardt, our Chief Medical Officer.
I’d like to start with our key achievements in 2024, starting with currently our most important commercial product, Cresemba, our antifungal for invasive mold infections. Cresemba continues to perform very well as demonstrated by the 20% increase of global in-market sales to more than $0.5 billion according to the latest available data for the 12-month period to
Read the full article here